FierceBiotech2d
Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...
The Pharma Letter1d
Kyorin offers Novartis timely new weapon in urticaria
Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...
ENDPOINTS NEWS2d
No­var­tis li­cens­es Ky­orin’s pre­clin­i­cal chron­ic hives can­di­date for $55M up­front
M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.
PMLiVE12d
KYORIN Pharmaceutical Co Ltd
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and ...
KELOLAND News15d
KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan
DELRAY BEACH, Fla., Feb. 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced ...
Yahoo Finance15d
KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan
Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and ...